21 / 31
PRIME: OS by post-progression anti-VEGF therapy (wt
RAS
)
Peeters M, et al. Eur J Cancer 2013;49(Suppl 4):abstract MC13-0024 (and poster).
PPT, post-progression therapy.
WT
RAS
= WT
KRAS
and
NRAS
exons 2, 3, 4.
Events
n (%)
Median, months
(95% CI)
+ anti-VEGF (n = 100)
80 (80)
38.1
− anti-VEGF (n = 246)
208 (85)
23.6
HR = 0.63 (95% CI, 0.48–0.81)
P = 0.0004
64
0
4
12 16 20
32 36
Proportion surviving, %
44
52 56 60
100
90
70
60
80
50
40
30
20
10
0
8
24 28
40
48
Months
OS from start of 1
st
-line therapy (both treatment arms combined)